Bridging the Gap: A Literature Review of Advancements in Obesity and Diabetes Mellitus Management

Author:

Pop Gheorghe Nicusor1ORCID,Manole Felicia2,Buleu Florina3ORCID,Motofelea Alexandru Catalin4,Bircea Silviu4ORCID,Popa Daian5ORCID,Motofelea Nadica6ORCID,Pirvu Catalin Alexandru7

Affiliation:

1. Center for Modeling Biological Systems and Data Analysis (CMSBAD), Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania

2. Surgical Disciplines Department, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania

3. Department of Cardiology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania

4. Department of Internal Medicine, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania

5. Doctoral School, Department of Surgery, Emergency Discipline, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania

6. Department of Obstetrics and Gynecology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania

7. Discipline of Surgical Emergencies, Department of Surgery II, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania

Abstract

This literature review explores advancements in obesity and diabetes mellitus diagnosis and treatment, highlighting recent innovations that promise more personalized and effective healthcare interventions. For obesity diagnosis, traditional methods like body mass index (BMI) calculations are now complemented by bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA) scans, with emerging biomarkers from “omics” technologies. Diabetes diagnosis has advanced with standard hemoglobin A1c (HbA1c) testing supplemented by novel measures such as advanced glycation end products (AGEs) and autoantibodies, alongside the use of artificial intelligence to enhance diagnostic accuracy. Treatment options for obesity are expanding beyond traditional methods. Minimally invasive bariatric surgeries, endoscopic procedures, fecal microbiota transplants (FMTs), and pharmaceuticals like GLP-1 receptor agonists (semaglutide, tirzepatide) show promising results. Cognitive behavioral therapy (CBT) and prescription digital therapeutics (PDTs) are also valuable tools for weight management. Diabetes treatment is also undergoing a transformation. Ultra-long-acting insulins and innovative oral insulin delivery methods are on the horizon. SGLT2 inhibitors and GLP-1 receptor agonists are proving to be effective medications for blood sugar control. Continuous glucose monitoring (CGM) systems and closed-loop insulin delivery are revolutionizing diabetes management, while stem cell therapy holds promise for the future. By integrating advanced diagnostic tools with personalized treatment plans, obesity and diabetes care are entering a new era. This personalized approach empowers patients and paves the way for improved health outcomes and a better quality of life.

Publisher

MDPI AG

Reference137 articles.

1. Centers for Disease Control and Prevention (2024). National Diabetes Statistics Report 2024.

2. Projection of the Future Diabetes Burden in the United States through 2060;Lin;Popul. Health Metr.,2018

3. World Health Organization (2022). Corrigendum WHO European Regional Obesity Report 2022, WHO.

4. Obesity Syndemic in the European Community: Towards a Systems Thinking Approach for Preventive Policies;Luca;Eur. Hear. J.,2024

5. 2024: The Year to Take European Action on Diabetes to the next Level;Torbeyns;Diabetologia,2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3